<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04190186</url>
  </required_header>
  <id_info>
    <org_study_id>00004318</org_study_id>
    <nct_id>NCT04190186</nct_id>
  </id_info>
  <brief_title>Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation</brief_title>
  <official_title>Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation (HYBRID AF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotronik, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is designed to compare two management strategies for the treatment of
      asymptomatic/subclinical atrial fibrillation after ablation based on data from the
      Biomonitor3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, subjects will be randomized (1:1) to conventional AF management vs.
      BioMonitor3®-guided AF management following ablation for persistent AF. Subjects will be
      followed for 15 months including a 3 month blanking period following AF ablation. The study
      subject population will include subjects with persistent atrial fibrillation (sustained AF
      episode lasting more than 7 days, but less than 1 year), refractory to at least one
      antiarrhythmic agent, according to current guideline indications for persistent AF ablation
      and ICM (BioMonitor3®) implantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2020</start_date>
  <completion_date type="Anticipated">September 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrillation (AF) burden defined as the mean amount of time spent in AF over a pre-specified period of time (excluding short AF episodes of ≤30 seconds) by the BioMonitor3®.</measure>
    <time_frame>Between months 3 and 15 after the ablation procedure (to exclude the first 3 month blanking period)</time_frame>
    <description>In the present study AF burden will be assessed at 3-month intervals during the 12 months following the blanking period (3-months post-ablation), and the difference at the end of the follow-up period of one year will serve as the primary comparison outcome between the two treatment groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant (&gt;30 min) atrial arrhythmia (atrial fibrillation, atrial flutter or atrial tachycardia) as detected and documented by BioMonitor3® after the performance of the index AF ablation procedure.</measure>
    <time_frame>Between enrollment and 15 months (excluding the initial 3-month blanking period) (assessed in a recurrent event analysis).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of symptomatic AF recurrence (regardless of duration).</measure>
    <time_frame>Between enrollment and 15 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of repeat AF ablation.</measure>
    <time_frame>Between enrollment and 15 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cardiac hospitalization.</measure>
    <time_frame>Between enrollment and 15 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths.</measure>
    <time_frame>Between enrollment and 15 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare utilization, defined as hospitalization for any cause, ED visits, and unplanned office visits.</measure>
    <time_frame>Between enrollment and 15 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Flutter or Tachycardia.</measure>
    <time_frame>Between months 3 and 15 after the ablation procedure (to exclude the first 3 month blanking period)</time_frame>
    <description>Incidence of atrial flutter or tachycardia after the index ablation procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of repeat procedures.</measure>
    <time_frame>Between months 3 and 15 after the ablation procedure (to exclude the first 3 month blanking period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse events requiring rehospitalization during follow-up.</measure>
    <time_frame>Between months 3 and 15 after the ablation procedure (to exclude the first 3 month blanking period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL) as assessed by Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire.</measure>
    <time_frame>Between months 3 and 15 after the ablation procedure (to exclude the first 3 month blanking period)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>BioMonitor3®-guided AF management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ICM obtained data will be actively used to guide and monitor treatment .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional AF Management</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treating physicians/nurses will be blinded to the AF episodes data from the monitor, but will be provided information on asystole, or ventricular arrhythmia events (for safety).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Insertable Cardiac Monitor</intervention_name>
    <description>Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.</description>
    <arm_group_label>BioMonitor3®-guided AF management</arm_group_label>
    <other_name>BioMonitor3®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Persistent atrial fibrillation (sustained AF episode lasting more than 7 days, but
             less than a year), refractory to at least one antiarrhythmic agent

          -  Underwent first AF ablation with successful BioMonitor3® implant before or at time of
             ablation

        Exclusion Criteria:

          -  Paroxysmal atrial fibrillation

          -  Long persistent atrial fibrillation (continuous atrial fibrillation that lasts more
             than 1 year)

          -  Permanent atrial fibrillation

          -  Left atrial diameter of 60 mm or greater

          -  Patients with CHF status prohibiting EP study and ablation, but may be re-considered
             for enrollment later after effective treatment

          -  Patients with metabolic derangements (e.g. renal/hepatic failure, electrolyte
             disturbance, etc.), prohibiting EP study and ablation or antiarrhythmic medical
             therapy (e.g. dofetilide, sotalol or amiodarone, etc.)

          -  Patients with an intra-cardiac thrombus, but may be re-considered for enrollment later
             after effective treatment

          -  Serious known concomitant disease with a life expectancy of &lt; 1 year

          -  Pregnancy or nursing

          -  Unwilling or unable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shelley L Secor-Socha, MS</last_name>
    <phone>585-275-7168</phone>
    <email>shelley.secor-socha@heart.rochester.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary Brown, MS, RN</last_name>
    <phone>585-275-8823</phone>
    <email>mary.brown@heart.rochester.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Bourret</last_name>
      <phone>585-276-7089</phone>
      <email>mary__bourret@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>David T Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L, Morillo CA, Haverkamp W, Weerasooriya R, Albenque JP, Nardi S, Menardi E, Novak P, Sanders P; STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015 May 7;372(19):1812-22. doi: 10.1056/NEJMoa1408288.</citation>
    <PMID>25946280</PMID>
  </reference>
  <reference>
    <citation>Huang DT, Monahan KM, Zimetbaum P, Papageorgiou P, Epstein LM, Josephson ME. Hybrid pharmacologic and ablative therapy: a novel and effective approach for the management of atrial fibrillation. J Cardiovasc Electrophysiol. 1998 May;9(5):462-9.</citation>
    <PMID>9607453</PMID>
  </reference>
  <reference>
    <citation>Kirchhof P, Calkins H. Catheter ablation in patients with persistent atrial fibrillation. Eur Heart J. 2017 Jan 1;38(1):20-26. doi: 10.1093/eurheartj/ehw260. Epub 2016 Jul 7. Review.</citation>
    <PMID>27389907</PMID>
  </reference>
  <reference>
    <citation>Willems S, Khairy P, Andrade JG, Hoffmann BA, Levesque S, Verma A, Weerasooriya R, Novak P, Arentz T, Deisenhofer I, Rostock T, Steven D, Rivard L, Guerra PG, Dyrda K, Mondesert B, Dubuc M, Thibault B, Talajic M, Roy D, Nattel S, Macle L; ADVICE Trial Investigators*. Redefining the Blanking Period After Catheter Ablation for Paroxysmal Atrial Fibrillation: Insights From the ADVICE (Adenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination) Trial. Circ Arrhythm Electrophysiol. 2016 Aug;9(8). pii: e003909. doi: 10.1161/CIRCEP.115.003909.</citation>
    <PMID>27516462</PMID>
  </reference>
  <reference>
    <citation>Schreiber D, Rostock T, Fröhlich M, Sultan A, Servatius H, Hoffmann BA, Lüker J, Berner I, Schäffer B, Wegscheider K, Lezius S, Willems S, Steven D. Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success. Circ Arrhythm Electrophysiol. 2015 Apr;8(2):308-17. doi: 10.1161/CIRCEP.114.001672. Epub 2015 Mar 5.</citation>
    <PMID>25744570</PMID>
  </reference>
  <reference>
    <citation>Reiffel JA, Camm AJ, Belardinelli L, Zeng D, Karwatowska-Prokopczuk E, Olmsted A, Zareba W, Rosero S, Kowey P; HARMONY Investigators. The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism. Circ Arrhythm Electrophysiol. 2015 Oct;8(5):1048-56. doi: 10.1161/CIRCEP.115.002856. Epub 2015 Jul 30.</citation>
    <PMID>26226999</PMID>
  </reference>
  <reference>
    <citation>Tondo C, Iacopino S, Pieragnoli P, Molon G, Verlato R, Curnis A, Landolina M, Allocca G, Arena G, Fassini G, Sciarra L, Luzi M, Manfrin M, Padeletti L; ClinicalService 1STOP Project Investigators. Pulmonary vein isolation cryoablation for patients with persistent and long-standing persistent atrial fibrillation: Clinical outcomes from the real-world multicenter observational project. Heart Rhythm. 2018 Mar;15(3):363-368. doi: 10.1016/j.hrthm.2017.10.038. Epub 2017 Oct 26.</citation>
    <PMID>29107190</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>David Huang</investigator_full_name>
    <investigator_title>Professor Medicine M&amp;D-Cardiology Div</investigator_title>
  </responsible_party>
  <keyword>Biotronik BioMonitor3</keyword>
  <keyword>ICM</keyword>
  <keyword>AF Ablation</keyword>
  <keyword>Atrial arrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

